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Abstract
Background: Many HIV-infected children in sub-Saharan Africa enter care at a late stage of disease. As preparation of the
child and family for antiretroviral therapy (ART) can take several clinic visits, some children die prior to ART initiation. This
study was undertaken to determine mortality rates and clinical predictors of mortality during the period prior to ART
initiation.
Methods: A prospective cohort study of HIV-infected treatment-naı ¨ve children was conducted between September 2007
and September 2010 at the HIV clinic at Macha Hospital in rural Southern Province, Zambia. HIV-infected children younger
than 16 years of age who were treatment-naı ¨ve at study enrollment were eligible for analysis. Mortality rates prior to ART
initiation were calculated and risk factors for mortality were evaluated.
Results: 351 children were included in the study, of whom 210 (59.8%) were eligible for ART at study enrollment. Among
children ineligible for ART at enrollment, 6 children died (mortality rate: 0.33; 95% CI:0.15, 0.74). Among children eligible at
enrollment, 21 children died before initiation of ART and their mortality rate (2.73 per 100 person-years; 95% CI:1.78, 4.18)
was significantly higher than among children ineligible for ART (incidence rate ratio: 8.20; 95% CI:3.20, 24.83). In both
groups, mortality was highest in the first three months of follow-up. Factors associated with mortality included younger age,
anemia and lower weight-for-age z-score at study enrollment.
Conclusions: These results underscore the need to increase efforts to identify HIV-infected children at an earlier age and
stage of disease progression so they can enroll in HIV care and treatment programs prior to becoming eligible for ART and
these deaths can be prevented.
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Introduction
Since 2003, antiretroviral treatment (ART) programs in sub-
Saharan Africa have rapidly scaled-up and currently provide
treatment to an estimated 356,000 HIV-infected children [1].
Reports from programs indicate that treatment outcomes among
children are comparable to those observed in resource-rich settings
[2]. However, many children enter care at a late stage of disease
progression, such that mortality rates during the first few months
of treatment are high [2]. The period between enrollment into
care and treatment initiation can extend for several months as
eligible children and their families are prepared for the burden and
challenges of ART [3]. This process can involve several clinic and
home visits, psychological assessments, ART literacy training,
adherence counseling, and identification of a family member or
friend to provide support (‘medicine companion’ or ‘treatment
supporter’) [4,5,6,7]. During this time, children also are diagnosed
and treated for any concurrent opportunistic infections. In
addition, children not eligible for ART at enrollment are
monitored, typically every three months, and may experience
rapid disease progression. Few programs report outcomes during
this period prior to ART initiation, but several studies among
adults [5,7,8,9,10,11] and children [3,6,12,13] indicate that
significant mortality occurs among both ART eligible and
ineligible individuals during this time of preparation and
evaluation.
This study was undertaken to determine mortality rates and
identify clinical predictors of mortality during the period prior to
ART initiation among both eligible and ineligible children
enrolled in an ART program in rural Zambia.
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Ethics Statement
The study was approved by the Government of Zambia
Ministry of Health, the Research Ethics Committee of the
University of Zambia and the Institutional Review Board of the
Johns Hopkins Bloomberg School of Public Health. Written
informed consent was obtained from parents or guardians and
assent was obtained from children 8–16 years of age.
Study Population
The study was conducted at Macha Hospital in a rural area of
Southern Province, Zambia. The study setting and population
have been described in detail elsewhere [14,15]. Briefly, Macha
Hospital is a district-level referral hospital administered by the
Zambian Brethren in Christ Church. Since 2005, Macha Hospital
has provided care to over 7000 HIV-infected adults and children
through the Government of Zambia’s antiretroviral treatment
program, with additional support from the President’s Emergency
Plan for AIDS Relief (PEPFAR) through the non-governmental
organization, AidsRelief.
Children with a positive HIV serologic test are referred to the
clinic from voluntary counseling and testing programs, outpatient
clinics and rural health centers. Early infant diagnosis based on
detection of HIV DNA has been available since February 2008.
Clinical care is provided without charge by medical doctors and
clinical officers, and adherence counseling by nurses and trained
counselors. Routine follow up occurs approximately every three
months. ART is initiated according to WHO guidelines at the
discretion of the doctors and clinical officers. At enrollment in the
clinic, children and their caregivers must attend two group
counseling sessions to avoid early attrition. Before ART initiation
an individual treatment preparation counseling session is provided,
and children must demonstrate their ability to adhere to non-ART
medications, including multivitamins and cotrimoxazole, over two
visits through self-report and pill counts. In addition, individuals
must identify a family member or friend to serve as a treatment
supporter.
Study Procedures
Beginning in September 2007, HIV-infected children younger
than 16 years seeking HIV care were eligible for enrollment into a
cohort study. Children were evaluated at study visits approxi-
mately every three months, at which time a questionnaire was
administered, the child was examined and a blood specimen was
obtained. The study questionnaire was designed to collect
information on demographics, the vital status and education of
the parents and primary caregiver, the child’s medical, medica-
tion, and vaccination history, disclosure of HIV status and
transportation to the clinic. During each physical examination,
height and weight were measured. As part of routine clinical care,
CD4
+ T cell counts and percentages were measured using the
Guava Easy CD4 system (Guava Technologies, Inc., Hayward,
CA). Hemoglobin was measured using an ABX Micros ES 60
Hematology Analyzer (Horiba Medical, France). For children who
missed study visits, home visits were attempted to ascertain their
status. For children who died, cause of death was ascertained
through verbal autopsy or through hospital or clinic records.
Information recorded before study enrollment was abstracted from
medical records.
Statistical Analysis
For the present analysis, all treatment-naı ¨ve children enrolled in
the study between September 2007 and September 2010 were
included. Children were followed until the first of either ART
initiation, death, loss to follow-up or September 1, 2010. Children
whose last visit occurred more than six months prior to September
1, 2010 were considered lost to follow-up.
Table 1. Baseline characteristics of treatment-naı ¨ve, HIV-
infected children receiving care at Macha Hospital, Zambia
from 2007–2010.
Study population
(n=351) N (%)
Median age in years (IQR)(n=351) 2.6 (1.4, 5.7)
,2 yrs 140 (39.9)
2–4 yrs 109 (31.1)
$5 yrs 102 (29.1)
Male (n=351) 158 (45.0)
Mother received PMTCT (n=348) 22 (6.3)
Vital status of parents (n=347)
Both alive 264 (76.1)
One parent died 64 (18.4)
Both died 19 (5.5)
Primary caregiver (n=348)
Mother/Father 272 (78.2)
Grandparent 39 (11.2)
Aunt/uncle 26 (7.5)
Other 11 (3.2)
Education of primary caregiver (n=337)
None 12 (3.6)
Primary 211 (62.6)
Secondary 110 (32.6)
Higher 4 (1.2)
Socioeconomic status (n=348)
#25
th percentile 233 (67.0)
26–50
th percentile 96 (27.6)
51–75
th percentile 17 (4.9)
76–100
th percentile 2 (0.6)
Median WAZ (IQR)
a (n=283) 22.2 (23.4, 21.3)
$22 133 (45.9)
,22t o23 70 (24.1)
,23 87 (30.0)
Median CD4% (IQR) (n=320) 20.7 (14.7, 27.6)
Severe immunodeficiency
b 129 (40.3)
WHO stage (n=264)
1 50 (18.9)
2 78 (29.6)
3 or 4 136 (51.5)
Eligible for ART
c (n=351) 210 (59.8)
ART: antiretroviral treatment ; IQR: interquartile range; PMTCT: prevention of
mother-to-child transmission; WAZ: weight-for-age z-score; WHO: World Health
Organization.
aAmong children ,10 years of age.
bDefined by age for all children according to the 2006 WHO guidelines.
cDefined retrospectively according to the WHO treatment guidelines in effect at
the time of study enrollment.
doi:10.1371/journal.pone.0029294.t001
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tively based on the WHO criteria in effect at the time of study
enrollment. At the beginning of the study, the 2006 WHO
treatment guidelines were in effect [16], which recommended
ART for all children with WHO stage 3 or 4 irrespective of
immunologic status. For children with WHO stage 1 or 2, ART
was recommended on the basis of immunologic status (#11
months: ,25%; 12–35 months: ,20%; $36 months: 15%).
Treatment guidelines were revised in 2008 [17], and ART was
recommended for all children younger than 12 months of age. For
children older than 12 months, ART initiation was based on
clinical (WHO stage 3 or 4) and immunologic (WHO stage 1 or 2
and ,20% for children 12–59 months or ,15% for children $5
years of age) status. The 2008 WHO treatment guidelines were
assumed to take effect in June, 2008. For children missing WHO
stage or CD4
+ T-cell percentage at enrollment, ART eligibility
Figure 1. Outcomes at the end of the study period, by eligibility status at study enrollment.
doi:10.1371/journal.pone.0029294.g001
Figure 2. Cumulative probability of ART initiation by eligibility status at study enrollment.
doi:10.1371/journal.pone.0029294.g002
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Immunologic and clinical parameters from within three months of
study enrollment were used to determine ART eligibility and
clinical and immunologic status at study enrollment. Weight-for-
age z-scores were calculated based on the WHO growth standards
[18] and children with z-scores below 22 and 23 were defined as
underweight and severely underweight, respectively. Severe
immunodeficiency was defined as CD4
+ T-cell percentage by
age for all children according to the 2006 WHO treatment
guidelines (#11 months: ,25%; 12–35 months: ,20%; 36–59
months: ,15%; $5 years: ,15%) [16]. Severe anemia was
defined as hemoglobin ,8 g/dL [19]. A measure of socio-
economic status (SES) was calculated based on the Demographic
and Health Survey SES scale used in Zambia [20]. SES
percentiles were based on the predetermined cutoffs (,25
th=0–
6; 26–50
th=7–12; 51–75
th=13–18; .75
th=19–24).
Kaplan-Meier survival methods were used to estimate the
cumulative probability of ART initiation and death. Survival
curves were compared between groups using the logrank test.
Mortality rates were calculated per 100 person-years at risk and
were compared using Poisson regression. Risk factors for mortality
were evaluated using Cox proportional hazards regression.
Characteristics associated with mortality in univariable analysis
(p,0.1) were considered for inclusion in the multivariable model.
All analyses were conducted in SAS for Windows version 9.2 (SAS
Institute Inc., Cary, NC) and Stata, version 11 (StataCorp LP,
College Station, Texas).
Results
During the study period, 363 treatment-naı ¨ve HIV-infected
children were invited to participate and 362 were enrolled. Three
hundred and fifty-one (97%) children had sufficient information to
determine their eligibility for ART and were included in the
analysis. Children were enrolled in the clinic for a median of 0.20
months (interquartile range [IQR]: 0, 4.16) prior to study
enrollment, and the median follow-up time in the study was
3.44 months (IQR: 0.92, 9.44). At study enrollment, the median
age was 2.6 years (IQR: 1.4, 5.7), 45.1% of children were male,
and 23.5% of children were single or double orphans (Table 1).
Over half (54.0%) of children were moderately (24.1%) or severely
underweight (30.0%) and the majority had severe disease: 40.3%
had severe immunodeficiency, 51.5% were classified as WHO
stage 3 or 4, and 59.8% were eligible for ART.
By the end of the study period, 192 (54.7%) children started
ART, 15 (4.3%) were lost to follow-up, 9 (2.6%) transferred to
another clinic, 27 (7.7%) died, and 108 (30.8%) were still in care
but not receiving ART. Children eligible for ART at enrollment
were significantly more likely to have started ART (p,0.0001)
and died (p=0.05) (Figure 1). Among children eligible at
enrollment, the median time from study enrollment to ART
initiation was 2.07 months (IQR: 0.92, 6.59) (Figure 2). At 12 and
24 months, the cumulative probability of ART initiation was
84.1% and 88.0%, respectively. Chart reviews were conducted
for 69 children who had either taken more than three months to
Table 2. Evaluation of delays in ART initiation among 69 children eligible for ART at enrollment who had either taken more than
three months to initiate ART or had been enrolled in the study for more than 3 months without starting ART.
N( % )
Delayed ART initiation 56 (81.2)
Family delay 19 (33.9)
Poor adherence 3 (5.4)
Family unpreparedness
a 4 (7.1)
Family unpreparedness and poor adherence 8 (14.3)
Child stopped coming to the clinic 4 (7.1)
Provider delay 16 (28.6)
Misinterpretation of laboratory results, HIV staging or eligibility criteria by clinician 10 (17.9)
Other 6 (10.7)
Medical delay 11 (19.6)
Hepatitis or elevated ALT 1 (1.8)
Tuberculosis 10 (17.9)
Combined family, provider or medical delay 9 (16.1)
Provider and family delay 6 (10.7)
Tuberculosis and poor adherence 2 (3.6)
Tuberculosis and family unpreparedness 1 (1.8)
Unknown 1 (1.8)
No delay 13 (18.8)
Eligible by WHO stage only
b 10 (76.9)
Other 3 (23.1)
Total 69 (100.0)
ART: antiretroviral treatment; ALT: alanine aminotransferase; WHO: World Health Organization.
aFamily unpreparedness included refusal to come at shorter intervals and problems with transportation.
bChildren who are underweight or have specific symptoms and opportunistic infections (e.g. prolonged diarrhea) are classified as WHO stage 3 at that visit. However,
they are not considered eligible for ART if their weight or symptoms improve with treatment at subsequent visits.
doi:10.1371/journal.pone.0029294.t002
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three months without starting ART to determine reasons for
potential delays in ART initiation (Table 2). The majority of
children (81.2%) were found to have an identifiable reason for
delay. The most common reason was delay on the part of the
family (33.9%), due to poor adherence of the child to other
medications, family unpreparedness to adhere to the more
frequent clinic visit schedule or the child missing clinic visits.
Other reasons included provider delay (28.6%), primarily due to
misinterpretation of laboratory results, HIV staging or eligibility
criteria by clinicians; medical delay (19.6%), primarily due to
treatment for tuberculosis; and a combination of family, provider
and medical delays (16.1%). Among children ineligible at
enrollment, the cumulative probability of ART initiation at 12
and 24 months was 35.3% and 41.0%, respectively (Figure 2).
Among the 27 children who died, the median time from study
enrollment to death was 1.90 months (IQR: 0.36, 3.41). Factors
contributing to death were available for 25 children and included
pneumonia (n=10), tuberculosis (n=10), undernutrition
(n=10), diarrhea (n=8), cerebral malaria (n=1), meningitis
(n=2), renal failure (n=1), hepatitis (n=1) and measles (n=1).
Place of death was available for 21 children; 16 (76.2%) children
died in the hospital and 5 (23.8%) children died at home. The
cumulative probabilities of death by 6, 12 and 24 months after
study enrollment were 9.9% (18.6% eligible, 3.2% ineligible),
12.0% (18.6% eligible, 6.1% ineligible), and 13.4% (24.4%
eligible, 6.1% ineligible; logrank test=0.0003; Figure 3), respec-
tively. The overall pre-ART mortality rate was 1.05 (95% CI:
0.72, 1.53) per 100 person-years. Among children ineligible for
ART, the mortality rate was 0.33 (95% CI: 0.15, 0.74) per 100
person-years. Among children eligible for ART, the mortality
rate was 2.73 (95% CI: 1.78, 4.18) per 100 person-years and was
significantly higher than among children ineligible for ART
(incidence rate ratio: 8.20; 95% CI: 3.20, 24.83). The mortality
rate was highest in the first three months after study enrollment
at 2.58 per 100 person-years (95% CI: 1.65, 4.05), and was
higher among children eligible for ART (eligible: 4.50; 95% CI:
2.75, 7.34; ineligible: 0.79; 95% CI: 0.25, 2.44; incidence rate
ratio: 5.70; 95% CI: 1.63, 30.55). Twenty-one (77.8%) of the
children who died were eligible for ART at study enrollment,
and this group was therefore more similar in characteristics at
study enrollment to the surviving children eligible for ART
(Table 3).
Among children eligible for ART at study enrollment, age,
WAZ score and anemia were associated with mortality in the
crude analysis and were further evaluated. In multivariable
analysis, lower WAZ score (HR for ,23 vs. $22: 7.63; 95%
CI: 1.80, 32.39) and anemia (HR: 3.50; 95% CI: 1.25, 9.77)
remained independently associated with a higher risk of mortality
(Table 4). Younger age was marginally independently associated
with mortality (hazard rate [HR] for ,2 years vs. $5 years: 3.58;
95% CI: 0.98, 13.09). CD4
+ T-cell percentage at study enrollment
and sex were not associated with mortality. The cumulative
probability of mortality six months after study enrollment was
8.0% for children with WAZ$22, 24.3% for children with WAZ
23t o22, and 35.0% for children with WAZ,23 (logrank
test=0.04; Figure 4A). The cumulative probability of mortality six
months after enrollment was 13.8% for children without anemia
and 34.6% for children with anemia (logrank test=0.001;
Figure 4B). The cumulative probability of mortality six months
after enrollment was 33.7% for children younger than 2 years of
age, 4.5% for children 2 to 4 years of age, and 9.2% for children 5
years of age or older (logrank test=0.01; Figure 4C). Similar risk
factors were found among children who were ineligible for ART at
study enrollment, although the number of children and deaths
were small and precluded a full evaluation (Table 4).
Figure 3. Cumulative probability of mortality by eligibility status at study enrollment.
doi:10.1371/journal.pone.0029294.g003
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Mortality among HIV-infected children in the period prior to
ART initiation was high, particularly in the first few months after
enrollment among children eligible for ART. Risk factors for
mortality included younger age, undernutrition and anemia, and
were similar among children eligible and ineligible for ART at
study enrollment.
Most treatment programs report on mortality and treatment
outcomes after initiation of ART and few have focused on the
period prior to ART initiation. However, this period should be
evaluated along with the interval after ART initiation as it
provides additional insight into the population of children reached
by the program and the effectiveness of the treatment program in
reducing mortality. A study of HIV-infected children from
Cambodia evaluated mortality prior to and after ART initiation
and found that the majority of deaths occurred before starting
ART [6]. Similar to this study, the majority of deaths occurred
within the first three months after enrollment and among children
who were eligible for ART. The overall mortality rate for children
who never started ART was 7.7 per 100 person-years and was
higher than the mortality rate among children receiving ART (2.0
per 100 person-years). Another study among 192 Ugandan
children who were ineligible for ART found that 19% progressed
to a WHO stage 3 or 4 event, death or ART eligibility after a
median of 605 days [13]. Most events, three of which were deaths,
occurred within the first year of follow-up. Predictors of
progression included lower CD4
+ T-cell percentage, higher viral
load, and younger age. Anemia was marginally associated with
progression but WAZ was not associated. Additional studies
reported that 1% of eligible and 3% of ineligible children in
Zambia died prior to ART initiation [3], and that 12.3% of ART-
naı ¨ve children compared to 9.5% of children on ART in
Mozambique died during follow-up [12]. Similar trends of high
pre-ART mortality in the first few months of follow-up and similar
risk factors were also found in studies of HIV-infected adults
[5,7,8,9,10]. In this study, the cumulative mortality prior to ART
initiation was 13.3% and was comparable to the cumulative
mortality of 14.4% among children initiating ART in this cohort
[15]. In addition, the mortality rate in the first three months after
study enrollment among children eligible for ART was compara-
ble to the mortality rate in the first three months after ART
initiation (unpublished data). While mortality rates differ between
programs depending on the characteristics of the population and
the rigor of ascertainment of deaths, these estimates indicate that a
significant proportion of children entering care are dying before
they initiate ART.
The majority of deaths occurred in the first few months after
study enrollment and during the period of preparation for ART.
The median time to ART initiation among eligible children was
Table 3. Comparison of characteristics at study enrollment between children who died, and children who were eligible and
ineligible for ART at study enrollment.
Children who died
(n=27) N (%)
Surviving children
eligible for ART
a
(n=189) N (%) p-value
b
Surviving children
ineligible for ART
a
(n=135) N (%) p-value
b
Male 10 (37.0) 87 (46.0) 0.38 61 (45.2) 0.44
Median age (IQR) 1.4 (0.7, 2.6) 2.0 (1.1, 4.7) 0.07 4.3 (2.1, 7.0) ,0.0001
,2 yrs 18 (66.7) 91 (48.2) 31 (23.0)
2–4 yrs 5 (18.5) 55 (29.1) 49 (36.3)
$5 yrs 4 (14.8) 43 (22.8) 0.20 55 (40.7) ,0.0001
Median WAZ (IQR)
c 23.7 (24.4, 22.1) 22.3 (23.6, 21.4) 0.03 21.8 (22.6, 20.9) 0.0002
$22 4 (21.1) 70 (42.9) 59 (54.6)
,22t o23 4 (21.1) 35 (21.5) 31 (28.7)
,23 11 (57.9) 58 (35.6) 0.12 18 (16.7) 0.0003
Median CD4% (IQR) 20.7 (14.9, 26.8) 17.0 (10.5, 21.1) 0.03 25.8 (22.1, 33.3) 0.001
Severe immunodeficiency
d 10 (41.7) 119 (67.2) 0.01 0 (0.0) ,0.0001
Median hemoglobin (IQR) 8.9 (7.7, 9.3) 9.5 (8.6, 10.5) 0.001 10.6 (9.3, 11.3) ,0.0001
,8 g/dL 8 (33.3) 21 (11.6) 0.004 7 (5.9) ,0.0001
WHO stage
1 1 (5.3) 11 (7.1) 38 (41.3)
2 3 (15.8) 21 (13.7) 54 (58.7)
3 or 4 15 (78.9) 121 (79.1) 0.51 0 (0.0) ,0.0001
Parent’s vital status
Both alive 19 (73.1) 151 (79.9) 94 (71.2)
One parent died 7 (26.9) 28 (14.8) 29 (22.0)
Both died 0 (0.0) 10 (5.3) 0.18 9 (6.8) 0.36
ART: antiretroviral treatment; WAZ: weight-for-age z-score; WHO: World Health Organization.
aART eligibility defined retrospectively according to the WHO treatment guidelines in effect at the time of study enrollment.
bp-value comparing surviving children to children who died.
cAmong children ,10 years of age.
dDefined by age according to the 2006 WHO guidelines.
doi:10.1371/journal.pone.0029294.t003
Pre-Treatment Mortality in HIV-Infected Children
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e292942.1 months. Other studies reported an average time of 4.7 months
to ART initiation among children in Cambodia [6], 0.9 months
among children in Lusaka, Zambia [3], one month among adults
in South Africa [7], and 4.3 months among adults in The Gambia
[11]. This period of preparation takes several clinic or home visits
to ensure caregivers are prepared to administer life-long
medication and be responsible for maintaining high adherence
in their children. This process can take longer in rural areas as
transportation and travel distance pose challenges, and necessitate
longer intervals between visits and synchronization of visits with
other family members [3]. Additional delays in ART initiation can
lengthen this period, and can be due to treatment for concurrent
tuberculosis or other illnesses, insufficient human resources
(primarily in the early years of a treatment program), incorrect
clinical or immunological staging by physicians, and social
problems in the family, such as lack of transportation, food
insecurity, no legal guardian, history of suboptimal adherence, lack
of disclosure of child’s status to another adult, denial of child’s
status or need for ART and ill health of the caregiver [6,21].
Similar reasons for delay were identified for 26.7% of children
eligible for ART at study enrollment in this study. Many of these
delays were warranted to stabilize the child’s health or ensure that
the family was prepared for the burden of administering ART to
the child. However, some delays also were attributable to clinician
judgment and could potentially be prevented through continued
training.
In this study, 77.8% of children who died were eligible for ART
and were therefore characterized by a younger age and later stage
of disease progression, including higher WHO stage, lower CD4
+
T-cell percentage, lower WAZ, and lower hemoglobin. These
characteristics were well-established risk factors for mortality
among HIV-infected children in sub-Saharan Africa prior to the
availability of ART [22,23,24]. Many children enroll in treatment
programs when eligible for ART [3], as did 60% of children in this
study. Identification of risk factors for mortality that could
distinguish those children at risk of early death might allow for
interventions to halt disease progression and prevent death. In this
study, risk factors for mortality among children eligible for ART
included younger age, severe undernutrition and severe anemia.
Interestingly, CD4
+ T-cell percentage was not predictive of early
mortality, although the median CD4
+ T-cell percentage was
relatively high in this group of children. These risk factors are
similar to risk factors for early mortality among children receiving
ART [3,25,26,27]. As a result of the late stage of disease at study
enrollment, most deaths occurred within the first few months of
follow-up before children could prepare for and start ART.
Consequently, continued efforts are needed to promote testing of
infants and children so that HIV-infected children can be
identified and enrolled into care at an earlier stage of disease. If
children could initiate treatment at lower levels of immunosup-
pression and with fewer concurrent illnesses, many of these pre-
ART deaths could be prevented.
There were several limitations to this study. First, the follow-up
time was relatively short and the number of observed deaths was
low, particularly among children ineligible for ART, which limited
our ability to evaluate risk factors for mortality in this group.
Second, study enrollment was used as a proxy for clinic
enrollment, as children had only been seen in the clinic for a
short duration prior to study enrollment. The reported mortality
rates may, therefore, underestimate the true mortality rate in this
population, as deaths may have occurred soon after clinic
enrollment which would not have been captured. However, the
loss to follow-up was low and it is unlikely that many deaths were
not reported. The mortality rate is likely to be accurate for the
group of children surviving long enough to enroll in the study.
Lastly, eligibility at study enrollment was defined retrospectively
based on immunologic and clinical criteria. Some misclassification
of eligibility status is likely to have occurred, as children with
undernutrition in this setting who are initially classified as WHO
stage 3 or 4 are not considered eligible for ART if they gain weight
on nutritional support and treatment. In addition, some children
were missing information on WHO stage or CD4
+ T-cell
percentage at study enrollment and were classified based on
immunologic or clinical criteria alone.
In summary, a significant number of HIV-infected children
enrolled in treatment programs die before initiating ART as a
Table 4. Risk factors for mortality among children eligible and ineligible for ART at study enrollment.
Children eligible for ART (n=210; 21 deaths)
Children ineligible for ART
(n=141; 6 deaths)
Crude HR (95% CI) Adjusted HR (95% CI) Crude HR (95% CI)
Male 0.53 (0.20, 1.37) — 2.47 (0.45, 13.49)
Age (years)
,2 3.31 (0.96, 11.42) 3.58 (0.98, 13.09) 3.90 (0.35, 43.23)
2–4 0.63 (0.11, 3.78) 1.03 (0.16, 6.60) 3.29 (0.34, 31.74)
$51 1 1
Weight-for-age z-score
a 0.74 (0.54, 1.01) 0.48 (0.26, 0.91)
$221 1 —
,22t o23 2.76 (0.62, 12.34) 4.47 (0.88, 22.74) —
,23 4.62 (1.23, 17.28) 7.63 (1.80, 32.39) —
CD4% (per 10) 1.17 (0.71, 1.95) — 0.53 (0.16, 1.75)
Severe immunodeficiency
b 0.92 (0.36, 2.36) — —
Hemoglobin ,8 g/dL 2.54 (1.48, 4.36) 3.50 (1.25, 9.77) 6.84 (1.25, 37.40)
ART: antiretroviral treatment; HR: hazard ratio.
aAmong children ,10 years of age.
bDefined by age according to the 2006 WHO guidelines.
doi:10.1371/journal.pone.0029294.t004
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need to increase efforts to identify HIV-infected children at an
earlier age and stage of disease so they can enroll in HIV care and
treatment programs prior to becoming eligible for ART. In this
way, they and their family can be prepared to initiate life-long
therapy and receive the full benefits of treatment.
Figure 4. Cumulative probability of mortality by WAZ (A), hemoglobin level (B), and age (C) at study enrollment among children
eligible for ART.
doi:10.1371/journal.pone.0029294.g004
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